Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$7.26
+0.8%
$9.28
$2.09
$14.84
$514.66M0.055.32 million shs2.25 million shs
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
$1.53
+0.7%
$1.44
$0.59
$2.31
$191.71M1.21.40 million shs898,654 shs
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$1.59
-0.6%
$2.06
$1.04
$2.86
$107.69M1820,234 shs249,227 shs
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$5.51
$4.00
$6.92
$200.47M2.16189,500 shs64,100 shs
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$19.50
+0.4%
$19.00
$10.06
$21.72
$366.99M0.8250,264 shs24,217 shs
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+1.69%+4.50%-16.76%-22.83%+37.93%
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
+1.33%+7.04%-15.56%+85.37%+151.45%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-1.84%-7.51%-24.17%+0.63%+1.91%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.00%0.00%0.00%0.00%0.00%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
-0.51%+3.85%-3.33%+6.41%+84.43%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
1.358 of 5 stars
3.31.00.00.03.11.70.0
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
1.0677 of 5 stars
3.51.00.00.01.71.70.0
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.4198 of 5 stars
3.21.00.04.71.82.50.0
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
1.8095 of 5 stars
2.53.00.00.02.51.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.67
Moderate Buy$15.00106.61% Upside
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
3.00
Buy$4.50194.12% Upside
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
2.33
Hold$3.1094.65% Upside
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
3.00
Buy$24.0023.08% Upside

Current Analyst Ratings

Latest ALT, NATR, CTMX, KMPH, and ATOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderweight ➝ Neutral
4/16/2024
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
4/2/2024
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
4/1/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
3/28/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/13/2024
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
DA Davidson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$21.50 ➝ $24.00
2/13/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
2/12/2024
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$4.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$430K1,196.89N/AN/A$2.75 per share2.64
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
N/AN/AN/AN/A$0.73 per shareN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$101.21M1.06N/AN/A($0.71) per share-2.24
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
$10.72M0.00N/A23.28$3.63 per share0.00
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$445.32M0.82$1.59 per share12.24$8.36 per share2.33

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$570K-$0.02N/AN/AN/A-0.56%N/A-0.26%5/14/2024 (Estimated)
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
-$8.56MN/A0.00N/AN/A-328.56%-16.12%-14.17%N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
$15.08M$0.7725.32N/A3.39%12.25%7.75%5/7/2024 (Confirmed)

Latest ALT, NATR, CTMX, KMPH, and ATOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/AN/A  
4/1/2024Q4 2023
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
N/A-$0.06-$0.06-$0.06N/AN/A
3/27/2024Q4 2023
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.33+$0.02-$0.12N/A$0.04 million
3/12/2024Q4 2023
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A$0.45+$0.45$0.44N/A$108.94 million
3/11/2024Q4 2023
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.02$0.01-$0.01$0.01$23.36 million$26.61 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
N/AN/AN/AN/AN/A
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
17.26
17.26
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
N/A
17.61
17.61
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.17
1.17
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
0.14
10.10
10.10
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
N/A
2.16
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
12.74%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
19.39%
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
79.40%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5970.89 million67.99 millionOptionable
Atossa Therapeutics, Inc. stock logo
ATOS
Atossa Therapeutics
12125.30 million115.53 millionOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
12067.73 million62.99 millionOptionable
Zevra Therapeutics, Inc. stock logo
KMPH
Zevra Therapeutics
2234.51 million34.13 millionOptionable
Nature's Sunshine Products, Inc. stock logo
NATR
Nature's Sunshine Products
81418.82 million17.94 millionOptionable

ALT, NATR, CTMX, KMPH, and ATOS Headlines

SourceHeadline
Some Shareholders May Object To A Pay Rise For Natures Sunshine Products, Inc.s (NASDAQ:NATR) CEO This YearSome Shareholders May Object To A Pay Rise For Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) CEO This Year
finance.yahoo.com - April 26 at 9:49 AM
What Is the Best $20 Stock to Buy in April? 3 Top Picks.What Is the Best $20 Stock to Buy in April? 3 Top Picks.
investorplace.com - April 26 at 6:39 AM
Natures Sunshine Products (NASDAQ:NATR) Shares Pass Above Two Hundred Day Moving Average of $17.98Nature's Sunshine Products (NASDAQ:NATR) Shares Pass Above Two Hundred Day Moving Average of $17.98
americanbankingnews.com - April 26 at 3:44 AM
Natures Sunshines Impact Report Highlights Achievements and Continued Commitment Toward SustainabilityNature's Sunshine's Impact Report Highlights Achievements and Continued Commitment Toward Sustainability
prnewswire.com - April 24 at 10:15 AM
Nature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature’s Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
finance.yahoo.com - April 23 at 7:40 PM
Natures Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ETNature's Sunshine Sets First Quarter 2024 Conference Call for Tuesday, May 7, 2024, at 5:00 p.m. ET
globenewswire.com - April 23 at 4:05 PM
Those who invested in Natures Sunshine Products (NASDAQ:NATR) five years ago are up 126%Those who invested in Nature's Sunshine Products (NASDAQ:NATR) five years ago are up 126%
finance.yahoo.com - April 21 at 1:52 PM
Natures Sunshine Products, Inc.s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?Nature's Sunshine Products, Inc.'s (NASDAQ:NATR) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
finance.yahoo.com - April 4 at 2:56 PM
Natures Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their PredictionsNature's Sunshine Products, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
finance.yahoo.com - March 15 at 7:55 AM
Natures Sunshine Shares Touch 52-Week High After 4Q UpdateNature's Sunshine Shares Touch 52-Week High After 4Q Update
marketwatch.com - March 14 at 8:49 AM
Why Natures Sunshine (NATR) Stock Is Up TodayWhy Nature's Sunshine (NATR) Stock Is Up Today
finance.yahoo.com - March 13 at 1:46 PM
Natures Sunshine Products, Inc.: Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Products, Inc.: Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 13 at 7:45 AM
Natures Sunshine: Q4 Earnings SnapshotNature's Sunshine: Q4 Earnings Snapshot
timesunion.com - March 12 at 8:59 PM
Natures Sunshine (NASDAQ:NATR) Misses Q4 Sales TargetsNature's Sunshine (NASDAQ:NATR) Misses Q4 Sales Targets
finance.yahoo.com - March 12 at 8:59 PM
Natures Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 EarningsNature's Sunshine Products Inc (NATR) Reports Significant Growth in Q4 and Full Year 2023 Earnings
gurufocus.com - March 12 at 6:04 PM
Natures Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial ResultsNature's Sunshine Reports Strong Fourth Quarter and Full Year 2023 Financial Results
globenewswire.com - March 12 at 4:05 PM
Preview: Natures Sunshine Productss EarningsPreview: Natures Sunshine Products's Earnings
benzinga.com - March 11 at 3:30 PM
Natures Sunshine (NATR) Q4 Earnings: What To ExpectNature's Sunshine (NATR) Q4 Earnings: What To Expect
finance.yahoo.com - March 11 at 10:30 AM
Nature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature’s Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
finance.yahoo.com - February 20 at 7:35 PM
Natures Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ETNature's Sunshine Sets Fourth Quarter and Full Year 2023 Conference Call for Tuesday, March 12, 2024, at 5:00 p.m. ET
globenewswire.com - February 20 at 4:05 PM
Is There Now An Opportunity In Natures Sunshine Products, Inc. (NASDAQ:NATR)?Is There Now An Opportunity In Nature's Sunshine Products, Inc. (NASDAQ:NATR)?
finance.yahoo.com - February 6 at 10:21 AM
Natures Sunshine Products: Unconvincing Trajectory Despite ImprovementsNature's Sunshine Products: Unconvincing Trajectory Despite Improvements
seekingalpha.com - January 31 at 4:43 AM
Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024Nature’s Sunshine Announces Participation at the 26th Annual Needham Growth Conference on January 19, 2024
finance.yahoo.com - January 2 at 8:03 PM
Natures Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the companyNature's Sunshine Products, Inc. (NASDAQ:NATR) is definitely on the radar of institutional investors who own 39% of the company
finance.yahoo.com - December 21 at 3:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Altimmune logo

Altimmune

NASDAQ:ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Atossa Therapeutics logo

Atossa Therapeutics

NASDAQ:ATOS
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.
CytomX Therapeutics logo

CytomX Therapeutics

NASDAQ:CTMX
CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Zevra Therapeutics logo

Zevra Therapeutics

NASDAQ:KMPH
KemPharm, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. It focuses on the treatment of serious medical conditions such as attention deficit hyperactivity disorder, pain, and other central nervous system disorders through its platform technology known as Ligand Activated Therapy. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.
Nature

Nature's Sunshine Products

NASDAQ:NATR
Nature's Sunshine Products, Inc., a natural health and wellness company, manufactures and sells nutritional and personal care products in Asia, Europe, North America, Latin America, and internationally. It offers general health products related to blood sugar support, bone health, cellular health, cognitive function, joint health, mood, sexual health, sleep, sports and energy, and vision. The company also provides immunity, cardiovascular, and digestive products; and personal care products, such as oils and lotions, aloe vera gels, herbal shampoos, herbal skin treatment, toothpaste, and skin cleansers, as well as weight management products. It offers its products under the Nature's Sunshine and Synergy WorldWide brands through a sales force of independent consultants. Nature's Sunshine Products, Inc. was founded in 1972 and is headquartered in Lehi, Utah.